Nurix enrolls first patient in bexobrutideg–venetoclax combination study
Company / institutional announcement · Nurix Therapeutics
Source published: · Event / reporting date: 2026-10-06
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Nurix announced the first patient enrollment in NX-5948-203, a Phase 1b/2 trial combining the investigational BTK degrader bexobrutideg with venetoclax in chronic lymphocytic leukemia. Initial enrollment focuses on relapsed or refractory disease. Conducted under the Roche collaboration, the study will assess safety, tolerability, and clinical activity to inform potential combination development across treatment settings.
Why it may matter
Combination testing could clarify how BTK degradation fits existing CLL regimens, but deeper responses and fixed-duration benefits remain hypotheses for evaluation.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections